Last reviewed · How we verify
vitamin D supplements and calcium
At a glance
| Generic name | vitamin D supplements and calcium |
|---|---|
| Sponsor | Cairo University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Arthralgia
- Nasopharyngitis
- Urinary tract infection
- Back pain
- Constipation
- Urinary Tract Infection
- Headache
- Back Pain
- Pain In Extremity
- Bronchitis
- Upper Respiratory Tract Infection
- Nausea
Key clinical trials
- Influence of β-hydroxy β-methyl Butyrate (HMB)Supplementation on Post-operative Muscle Mass and Function in Female Athletes (PHASE2)
- Romosozumab Use to Build Skeletal Integrity (PHASE4)
- Prunes Preventing Bone Loss in Perimenopause (NA)
- Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta (PHASE3)
- Bone Metabolism in 12-21 Year Olds Undergoing GLP-1 Receptor Agonist Therapy
- Therapeutic Diets in Alzheimer's Disease (NA)
- Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis (NA)
- Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- vitamin D supplements and calcium CI brief — competitive landscape report
- vitamin D supplements and calcium updates RSS · CI watch RSS
- Cairo University portfolio CI